(Reuters) -The U.S. Food and Drug Administration is probing the death of a patient who developed harmful antibodies after taking Takeda Pharmaceuticals' blood disorder therapy, the health regulator said on Friday.
The pediatric patient died about 10 months after starting Takeda's drug Adzynma as a preventive therapy, the agency said.
The child had congenital thrombotic thrombocytopenic purpura (cTTP), an inherited condition that causes blood clots in small vessels and can lead to organ damage.
The FDA said the child developed antibodies that blocked the activity of ADAMTS13, an enzyme critical for blood clotting.
Takeda did not immediately respond to Reuters request for comment.
Adzynma, approved in 2023 as the first therapy for cTTP, replaces the ADAMTS13 protein to help prevent dangerous blood clots.
The agency added it has received multiple postmarketing reports of patients developing neutralizing antibodies to ADAMTS13 after treatment with Adzynma.
(Reporting by Kamal Choudhury in Bengaluru; Editing by Vijay Kishore)
The Excursion to Monetary Proficiency: Individual budget Triumphs- Gov’t approves millions for border cities in North under Hezbollah fire
- The Best Games On the planet
- 1st-ever disease gene fix, Alzheimer's blood test: 7 medical breakthroughs in 2025
- Tech giants accused of not complying with Australian social media ban
- Kiefer Sutherland arrested after allegedly assaulting a ride-share driver in L.A.
- After fleeing past Hezbollah fighting, some Israelis on northern border vow to stay
- Getting through a Lifelong Change: Individual Examples of overcoming adversity
- 10 Demonstrated Tips to Expand Your New Android Cell phone: A Thorough Aide
